Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Phase 4

Completed

• Conditions: Metabolic Syndrome; Insulin Resistance

• Registration Number: NCT00364221
• Lead Sponsor: University of Colorado, Denver

Brief Summary

The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Primary Completion: 2006-07
• Study First Submitted: 2006-08-14
• Study First Submitted QC: 2006-08-14
• Study First Posted: 2006-08-15
• Study Completion: 2006-10
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-20
• Last Update Posted: 2012-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Nondiabetic subjects with an NCEP/ATP III diagnosis of the metabolic syndrome

Exclusion Criteria

• Statin Medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

University of Colorado at Denver and Health Sciences Center General Clinical Research Center; 🇺🇸 Denver, Colorado, United States